Weight gain in antipsychotic-naive patients: A review and meta-analysis

Psychological Medicine

Volumn 40, Issue 2, 2010, Pages 187-200

  Tarricone, I ^a   Ferrari Gozzi, B ^a   Serretti, A ^a   Grieco, D ^a   Berardi, D ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antipsychotic agents; Antipsychotic naive; BMI gain; First episode psychosis; Weight gain

Indexed keywords

BODY MASS; HOSPITALIZATION; HUMAN; META ANALYSIS; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW; WEIGHT GAIN;

BODY MASS INDEX; HOSPITALIZATION; HUMANS; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 76649090935     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291709990407     Document Type: Review

References (60)

1. Addington J, Mansley C, Addington D (2003). Weight gain in first-episode psychosis. Canadian Journal of Psychiatry 48, 272-276.
2. Allison DB, Casey DE (2001). Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62, 22-31.
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain; a comprehensive research synthesis. American Journal of Psychiatry 156, 1686-1696.
4. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodríguez-Sánchez JM, Pérez-Iglesias R, Vázquez-Barquero JL (2008). Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22, 547-562.
5. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B (2006). Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first episode psychosis patients: a randomized controlled trial. Journal of Clinical Psychiatry 67, 1253-1260.
6. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obesity Research 12, 362-368.
7. Arranz B, San L, Duenas RM, Centeno M, Ramirez N, Salavert J, Del Moral E (2007). Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 22, 11-15.
8. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL (2001). Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry 62, 45-66.
9. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001). Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. Journal of Clinical Psychiatry 62, 231-238.
10. Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM (2007). Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. Journal of Clinical Psychiatry 68, 597-603.
11. Brown S, Birtwistle J, Roe L, Thompson C (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29, 697-701.
12. Caballero E (2003). Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectrums 11 (Suppl. 2), 19-22.
13. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006). Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 83, 87-93.
14. Egger M, Smith GD, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634.
15. Ganguli R, Brar JS, Ayrton Z (2001). Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research 49, 261-267.
16. Gentile S (2006). Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety 29, 303-319.
17. Haupt DW (2006). Differential metabolic effects of antipsychotic treatments. European Neuro-psychopharmacology 16 (Suppl. 3), S149-S155.
18. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O (2002). Glucose intolerance with atypical antipsychotics. Drug Safety 25, 1107-1116.
19. Henderson DC (2007). Weight gain with atypical antipsychotics: evidence and insights. Journal of Clinical Psychiatry 68 (Suppl. 12), 18-26.
20. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 157, 975-981.
21. Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Journal Clinical Psychiatry 64, 5-19.
22. Kelly DL, Conley RR, Carpenter WT (2005). First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 65, 1113-1138.
23. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal Clinical Psychiatry 62, 92-100.
24. Kurzthaler I, Fleischhacker WW (2001). The clinical implications of weight gain in schizophrenia. Journal of Clinical Psychiatry 62, 32-37.
25. Lee E, Leung CM, Wong E (2004). Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Journal of Clinical Psychiatry 65, 864-866.
26. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
27. 2-year follow-up of first episode schizophrenic patients. Journal of Substance Use 7, 15-18.
28. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup ST, Lieberman JA (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80, 19-32.
29. McGavin JK, Goa KL (2002). Aripiprazole. CNS Drugs 16, 779-786.
30. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, Eggleston A (2003). Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Canadian Journal of Psychiatry 48, 689-694.
31. Meyer JM (2002). A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry 63, 425-432.
32. Munafò MR, Flint J (2004). Meta-analysis of genetic association studies. Trends in Genetics 20, 439-444.
33. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL (2007). A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. Journal of Clinical Psychiatry 68, 1733-1740.
34. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran J, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL (2008a). Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Research 99, 13-22.
35. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Terán JM, Carrasco-Marín E, Mata I, Crespo-Facorro B (2008b). Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Journal of Clinical Psychopharmacology 28, 289-295.
36. Perkins DO (1999). Adherence to antipsychotic medications. Journal of Clinical Psychiatry 60 (Suppl. 21), 25-30.
37. Perkins DO (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63, 1121-1128.
38. RevMan (2003). Review Manager (RevMan) (computer program). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2003 (http://www.cochrane-net.org/download/revman/ revman42.exe).
39. Reynolds GP, Zhang ZJ, Zhang XB (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359 2086-2087.
40. 2C receptor gene and clozapine-induced weight gain. American Journal of Psychiatry 160, 677-679.
41. Robinson DG, Woerner MG, Delman HM, Kane JM (2005). Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin 31, 705-722.
42. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004). The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sciences 74, 1999-2008.
43. Saddichha S, Ameen S, Akhtar S (2008a). Predictors of antipsychotic-induced weight gain in first episode psychosis. Journal of Clinical Psychopharmacology 28, 27-31.
44. Saddichha S, Manjunatha N, Ameen S, Akhtar S (2007a). Effects of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. Journal of Clinical Psychiatry 68, 1793-1798.
45. Saddichha S, Manjunatha N, Ameen S, Akhtar S (2008b). Diabetes and schizophrenia-effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatrica Scandinavica 117, 342-347.
46. Saddichha S, Shaul A, Sayeed A (2007b). Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode of schizophrenia: a six-week prospective study in Indian female patients. Schizophrenia Research 95, 247.
47. Scheen AJ, De Hert MA (2007). Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes and Metabolism 33, 169-175.
48. Tarricone I, Serretti A, Ferrari Gozzi B, Mandelli L, Grieco D, Mellini L, Bigini S, Berti B, Berardi D (2008). Metabolic side effects of second generation antipsychotic agents in antipsychotic-naive patients: one-month prospective evaluation. Psychiatry Research 157, 269-271.
49. Taylor DM, McAskill R (2000). Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatrica Scandinavica 101, 16-32.
50. Templeman LA, Reynolds GP, Arranz B, San L (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 15, 195-200.
51. Wetterling T, Mussigbrodt H (1999). Weight gain: side effect of atypical neuroleptics? Journal of Clinical Psychopharmacology 14, 316-321.
52. Wirshing DA (2001). Adverse effects of atypical antipsychotics. Journal of Clinical Psychiatry 62, 7-10.
53. Wirshing DA (2004). Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry 65 (Suppl. 18), 13-26.
54. Wirshing DA, Pierre JM, Wirshing WC (2002). Sleep apnea associated with antipsychotic-induced obesity. Journal of Clinical Psychiatry 63, 369-370.
55. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999). Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry 60, 358-363.
56. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 186, 572-578.
57. Wu RR, Zhao JP, Zhai JG, Guo XF, Guo WB (2007). Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Journal of Clinical Psychopharmacology 27, 374-379.
58. Yap HL, Mahendran R, Lim D, Liow PH, Lee A, Phang S, Tiong A (2001). Risperidone in the treatment of first episode psychosis. Singapore Medical Journal 42, 170-173.
59. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. British Journal of Psychiatry 184, 58-62.
60. Zhang ZJ, Yao ZJ, Zhang XB, Chen JF, Sun J, Yao H, Hou G, Zhang XB (2003). No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacologica Sinica 24, 235-240.